DUBLIN--(http://www.researchandmarkets.com/research/l7xjmp/contraception) has announced the addition of the "Contraception Market Report 2013" report to their offering.)--Research and Markets (
This Key Note Market Update analyses the various forms of contraception available in the UK. It covers oral contraceptives, condoms, implants, injections, caps and diaphragms, as well as intra-uterine systems (IUSs). Most of these products are subsidised by the National Health Service (NHS); for example, male condoms are available free from NHS community contraceptive clinics, while they can also be purchased from retailers.
The UK contraception market grew in value by 2.8% in 2012, after an increase of 2.6% in 2011. The hormone-based products sector remained the largest sector in both volume and value terms, and accounted for 55.9% of the total market in terms of value. Within the market for hormone-based contraceptives, expenditure on progesterone-only contraceptives has been growing rapidly in recent years.
Oral products remain the most popular primary method of contraception; according to the NHS, it was the primary contraceptive method of 45% of all women who attended NHS community contraceptive clinics in 2011/2012. According to the NHS, more than 50% of those aged 18 to 24 use oral contraceptives as their primary method of contraception.
Despite the Government's campaign in recent years to stem the spread of sexually transmitted infections (STIs), the number of new STI diagnoses remains high. Data from the Health Protection Agency (HPA) revealed that there were over 400,000 new STI diagnoses in 2009, up from around 300,000 in 2005. There was a small fall in the number of diagnoses in 2010 (of 1.6%), however this number rose again in 2011, by 1.7%, offsetting the decline in 2010.
Demand for long-acting reversible contraceptives (LARCs) among women has been slowly increasing over the last few years. According to the NHS, over 1 million LARCs were dispensed in England in 2011/2012, with an increase of over 200,000 from 2007/2008. In particular, there has been strong growth in the number of prescriptions for intra-uterine devices (IUDs), as well as increases in the number of implants.
Key Note forecasts that, between 2013 and 2017, the total market for contraception will grow by 14.1%. Hormone-based products will continue to account for the largest proportion of the contraception market and its value is projected to grow by 17%. The markets for intra-uterine products and barrier products are also projected to grow steadily over the forecast period, by 17.2% and 9%, respectively. Falling demand for some types of contraceptive methods, such as spermicides and vasectomies, is expected to continue over the next 5 years.
- Ansell (Uk) Ltd
- Janssen-Cilag Ltd
- Organon Laboratories Ltd
- Pfizer Ltd
- Ssl International Plc
- Bayer Plc
For more information visit http://www.researchandmarkets.com/research/l7xjmp/contraception